Ascendis Pharma A/S

NASDAQ•ASND

執行長: Mr. Jan Moller Mikkelsen

板塊: Healthcare

行業: Biotechnology

上市日期: 2015-01-28

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

聯絡資訊

Tuborg Boulevard 12, Hellerup, 2900, Denmark

45-70-22-22-44

ascendispharma.com

市值

$14.82B

本益比 (TTM)

-55.9

19.7

股息率

52周最高

$248.60

52周最低

$124.06

52周範圍

94%

排名55Top 80.0%

2.6

F-Score

改良版 Piotroski 分析

基於 10 年期基本面

疲弱 • 2.6 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2016-2025

財務儀表板

Q4 2025 數據

營業收入

$285.45M+0.00%

近4季度走勢

每股收益

-$0.63+0.00%

近4季度走勢

自由現金流

$78.44M+0.00%

近4季度走勢

2025 Annual 財報亮點

核心亮點

Revenue Surge Driven by YORVIPATH Total revenue €720.1M, up €356.5M; YORVIPATH sales €477.4M, up €448.7M compared to 2024.

Operating Loss Significantly Reduced Operating loss €136.3M, improvement €142.5M versus prior year's €278.8M loss reported for 2024.

Positive Operating Cash Flow Cash flow from operations €53.9M, a €360.1M improvement from prior period cash usage of €306.2M.

Pipeline Milestones Achieved Secured Novo Nordisk deal; TransCon CNP NDA priority review with FDA PDUFA goal February 28, 2026.

關注風險

Future Viability Concerns Significant future losses incurred, making future viability assessment difficult; total equity deficit €162.8M.

Financing Dependency Risk Failure to secure needed capital could force delay, limit, or cease commercialization activities and product development.

Product Success Uncertainty Substantial dependence on product candidates succeeding in clinical trials or receiving necessary regulatory approval.

Supply Chain Single Source Reliance on third-parties for manufacturing, including single-source suppliers, risks material adverse business impact.

未來展望

Vision 2030 Blockbuster Goal Pursue Vision 2030 goal: achieve >€5B revenue for key products via worldwide commercialization efforts.

Pipeline Expansion Focus Expand pipeline in Endocrinology Rare Disease and pursue TransCon opportunities in >€5B indications.

Global Commercialization Execution Execute integrated organization strategy across US, Europe Direct, and International Markets for product launches.

Technology Platform Leverage Maximize value creation by leveraging TransCon technology platform through strategic collaborations with market leaders.

同行對比

營業收入 (TTM)

BAX

$11.24B

+5.7%

BMRN

$3.22B

+12.9%

RPRX

$2.38B

+5.1%

毛利率 (最新季度)

RPRX

100.0%

+0.0pp

IONS

96.1%

-0.7pp

EXEL

95.6%

+0.1pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
MRNA	$22.83B	-8.0	-30.1%	15.5%
ROIV	$21.13B	-25.4	-18.3%	4.0%
RPRX	$20.32B	26.6	11.9%	45.6%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

39.0%

高速增長

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

50%

現金流需要關注

深度研究

下次財報:2026年4月29日

每股收益:-

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料